In 2016, the top 20 pharmaceutical companies’ sales of products gained through mergers and acquisitions are expected to match those of products developed within the companies. By net present value, only 36% of phase III drugs were internally developed, whereas 31%, 31% and 2% of them were obtained through acquisitions of companies, in-licensing and acquisitions of products, respectively. In 2014, Roche was the company with the highest share of sales from acquired drugs, at 77%. This proportion is predicted to reach 85% in 2018. Although only 16% of Bristol-Myers Squibbs’s 2014 sales were from acquisitions, that share is projected to jump to 52% in 2018 and 61% in 2020, making it the company anticipated to grow the most through acquisitions. This strategy is not universal, however. For example, Gilead’s proportion of sales of acquired drugs is currently 62% and expected to drop to 26% in 2018 and 20% in 2020.

Source: EvaluatePharma